• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

NLA 2025: Bempedoic Acid for ASCVD Prevention and LDL-C Reduction

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Bempedoic acid is an effective option for statin-intolerant patients or those needing additional low-density lipoprotein cholesterol (LDL-C) reduction, with clinical trials showing cardiovascular benefits, key drug-drug interaction...

ASCO 2025: Vepdegestrant’s Efficacy and Safety in ER+/HER2- Advanced Breast Cancer

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates. Read More

Survey-Based Analysis of Pharmacogenomics Education Integration

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Gaps in curricula emphasize a need for enhanced interprofessional training to improve patient care. Read More

Reducing the Risks: Managing CRS, ICANS, and Skin Reactions in Emerging Lung Cancer Therapies

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Experts discuss BiTE therapy in treating lung cancers, focusing on innovative agents like tarlatamab and amivantimab, and their toxicity management. Read More

MRD Monitoring May Help Redefine Long-Term Goals in Myeloma Therapy

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

NLA 2025: The Earlier LDL Cholesterol Is Lowered, the Greater the Cardiovascular Risk Reduction

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Kausik K. Ray, MD, discussed the importance of early, aggressive, and sustained LDL-C lowering for atherosclerotic cardiovascular disease prevention, highlighting that the magnitude of cardiovascular risk reduction is independent of the...
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT